Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
155.39
-1.20 (-0.77%)
Nov 20, 2026, 10:11 AM EST - Market open
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $208.54. The average 1-year stock price forecast is 34.20% higher than the current stock price, while the lowest is $150 (-3.47%) and the highest is $253 (+62.82%).
Price Target: $208.54 (+34.20%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 21 | 20 | 20 | 21 | 21 | 20 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 28 | 28 | 29 | 29 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $185 → $191 | Hold | Maintains | $185 → $191 | +22.92% | Nov 13, 2026 |
| Bernstein | Bernstein | Buy Maintains $218 | Buy | Maintains | $218 | +40.29% | Nov 4, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $207 → $224 | Buy | Reiterates | $207 → $224 | +44.15% | Nov 4, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Nov 3, 2026 |
| BMO Capital | BMO Capital | Hold Maintains $150 | Hold | Maintains | $150 | -3.47% | Nov 3, 2026 |
Financial Forecast
Revenue This Year
3.99B
from 2.86B
Increased by 39.62%
Revenue Next Year
4.58B
from 3.99B
Increased by 14.75%
EPS This Year
10.59
from 6.39
Increased by 65.72%
EPS Next Year
12.30
from 10.59
Increased by 16.14%
EPS and Forward PE are based on non-GAAP adjusted numbers.